Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: Lessons learned from a negative trial

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 347-350

  Konstantinopoulos, Panagiotis A ^a   Cannistra, Stephen A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB;

CANCER CHEMOTHERAPY; CANCER RECURRENCE; EDITORIAL; GENE FUNCTION; GENE MUTATION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; MUTATION; OVARIAN NEOPLASMS;

EID: 84856731422     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1489     Document Type: Editorial

References (25)

1. Cass I, Baldwin RL, Varkey T, et al: Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 97:2187-2195, 2003 (Pubitemid 36444059)
2. Tan DS, Rothermundt C, Thomas K, et al: "BRCAness" syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 26:5530-5536, 2008
3. Brody LC: Treating cancer by targeting a weakness. N Engl J Med 353:949-950, 2005
4. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917-921, 2005 (Pubitemid 40559006)
5. McCabe N, Turner NC, Lord CJ, et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66:8109-8115, 2006 (Pubitemid 44299177)
6. Schelman WR, Sandhu SK, Moreno Garcia V, et al: First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc). J Clin Oncol 29:219s, 2011 (suppl 15; abstr 3102)
7. Drew Y, Ledermann JA, Jones A, et al: Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol 29:220s, 2011 (suppl 15; abstr 3104)
8. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
9. Audeh MW, Carmichael J, Penson RT, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245-251, 2010
10. Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512-2519, 2010
11. Kaye SB, Lubinski J, Matulonis U, et al: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 10.1200/JCO.2011.36.9215
12. Markman M, Kennedy A, Webster K, et al: Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78(3 Pt 1):369-372, 2000
13. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001 (Pubitemid 32642183)
14. Capolongo L, Belvedere G, D'Incalci M: DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemother Pharmacol 25:430-434, 1990 (Pubitemid 20069342)
15. Safra T, Borgato L, Nicoletto MO, et al: BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther 10:2000-2007, 2010
16. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
17. Yang D, Khan S, Sun Y, et al: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557-1565, 2011
18. Vencken PM, Kriege M, Hoogwerf D, et al: Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 22:1346-1352, 2011
19. Edwards SL, Brough R, Lord CJ, et al: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111-1115, 2008 (Pubitemid 351317441)
20. Sakai W, Swisher EM, Karlan BY, et al: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-1120, 2008 (Pubitemid 351317449)
21. Norquist B, Wurz KA, Pennil CC, et al: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29:3008-3015, 2011
22. Konstantinopoulos PA, Spentzos D, Karlan BY, et al: Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555-3561, 2010
23. Hennessy BT, Timms KM, Carey MS, et al: Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28:3570-3576, 2010
24. Baldwin RL, Nemeth E, Tran H, et al: BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study. Cancer Res 60:5329-5333, 2000
25. Graeser M, McCarthy A, Lord CJ, et al: A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16:6159-6168, 2010